Hedvig Mildner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hedvig Mildner has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Yalcinkaya
Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, Turkey
1 shared publication Anette Johnsson
Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
1 shared publication- Anish Behere
Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
1 shared publication - Axel Cederholm
Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
1 shared publication Constantin Habimana Mugabo
Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
1 shared publicationLaura Gonzalez
Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 22 February 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-6
No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines
Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.
- 22 February 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-6
Open AccessNo link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines
Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.